Imugene Ltd (ASX: IMU, OTC: IUGNF) chief medical officer Dr. Paul Woodard and managing director and CEO Leslie Chong talked with Proactive’s Tylah Tully about the latest results from the Phase 1b clinical trial of Azer-cel, the company’s CD19 CAR-T therapy.
Dr. Woodard, speaking from 2025 Tandem Meetings in Honolulu, shared the excitement around the trial's findings.
Azer-cel is being developed for patients who have relapsed after multiple lines of treatment.
The latest data reveals a 57% complete response rate, meaning no detectable lymphoma in these patients.
Chong highlighted that the addition of a low dose of IL-2 to Azer-cel has contributed to T-cell proliferation, helping patients’ immune systems fight back.
She emphasised that seeing durable responses in patients who have exhausted multiple treatment options is a significant achievement.
Dr. Woodard also underscored the importance of these results, stating that some patients are experiencing long-lasting remissions, with one individual remaining in complete remission for over ten months.
These findings reinforce the potential of Azer-cel in addressing an unmet need in relapsed and refractory lymphoma patients.